CAMBRIDGE, Mass., April 17, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Frank Gentile, PhD, Chief Executive Officer, presented and participated in one-on-one meetings at the 23rd Annual Needham Virtual Healthcare Conference on April 5, 2024. Frank Gentile, PhD, will also attend and participate in […]
CAMBRIDGE, Mass. – April 12, 2019 – Casma Therapeutics, a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that the company has been named a winner of the Best Places to Work award sponsored by the Boston Business Journal.
The Boston Business Journal’s Best Places to Work awards are designed to honor employers in the greater Boston area who go beyond the norm to foster a supportive, dynamic and meaningful work environment for their employees. Casma was honored in the “extra small” category, which covers companies with fewer than 50 employees.
“The strength of Casma’s science is embedded in the productivity of our team,” said Keith Dionne, Casma’s chief executive officer. “In the year since our launch, we have made it a top priority to ensure Casma is a nurturing, fun and invigorating place to work. This award is testament to those efforts, and we are delighted to be selected.”
The Boston Business Journal will recognize this year’s 79 honorees at an awards ceremony on June 19 at the World Trade Center in Boston. Honorees will also be featured in a special June 21 edition of the Boston Business Journal.
About Casma Therapeutics
Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development. Casma uses several approaches to intervene at strategic points throughout the autophagy-lysosome system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens. By boosting autophagy, Casma expects to be able to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, among other indications. Casma was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass. For more information, please visit www.casmatx.com.
Contacts
Ten Bridge Communications
Stephanie Simon, 617-581-9333
stephanie@tenbridgecommunications.com
Keep reading:
-
April 17, 2024Casma Therapeutics to Participate at 23rd Annual Needham Virtual Healthcare Conference and at UBS Virtual Targeted Protein Degradation Day
-
February 28, 2024Casma Therapeutics to Present at the Gordon Research Conference on Autophagy in Stress, Development, and Disease
CAMBRIDGE, Mass., February 28, 2024– Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Leon Murphy, Ph.D., Chief Scientific Officer and Dan Baird Ph.D., Vice President, Molecular Discovery will participate in the Gordon Research Conference on Autophagy in Stress, Development, and Disease in Lucca, Italy. Dr. […]